Related Experiment Video
Updated: Jun 30, 2026
Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
Published on: August 25, 2019
A prospective randomized controlled trial of preimplantation genetic screening in the "good prognosis" patient
Liza R Meyer1, Sigal Klipstein, William D Hazlett
1Karande and Associates, Hoffman Estates, Illinois 60194, USA.
Objective:
To determine whether the routine use of preimplantation genetic screening (PGS) in "good prognosis" women improves in vitro fertilization (IVF) cycle outcome.
Design:
Randomized, controlled, prospective clinical study.
Setting:
Private infertility clinic.
Patient(S):
Infertile women predicted to have a good prognosis as defined by: age <39 years, normal ovarian reserve, body mass index <30 kg/m(2), presence of ejaculated sperm, normal uterus,
Intervention(S):
Patients were randomized to the PGS group or the control group on day 3 after oocyte retrieval; 23 women underwent blastomere biopsy on day 3 after fertilization (PGS group), and 24 women underwent routine IVF (control group). All embryos were transferred on day 5 or 6 after fertilization.
Main Outcome Measure(S):
Pregnancy, implantation, multiple gestation, and live birth rates.
Result(S):
No statistically significant differences were found between the PGS and control groups with respect to clinical pregnancy rate (52.4% versus 72.7%). However, the embryo implantation rate was statistically significantly lower for the PGS group (31.7% versus 62.3%) as were the live birth rate (28.6% versus 68.2%) and the multiple birth rate (9.1% versus 46.7%).
Conclusion(S):
In a "good prognosis" population of women, PGS does not appear to improve pregnancy, implantation, or live birth rates.
